Amgen Inc. $AMGN Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.4% in the 1st quarter, Holdings Channel reports. The fund owned 825,116 shares of the medical research company’s stock after selling 19,940 shares during the period. California State Teachers Retirement System’s holdings in Amgen were worth $290,317,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Norges Bank purchased a new position in shares of Amgen during the 4th quarter valued at approximately $2,164,162,000. Capital World Investors grew its position in Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after buying an additional 4,302,237 shares during the period. State Street Corp increased its holdings in Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after buying an additional 1,287,310 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. Finally, Amundi boosted its stake in shares of Amgen by 41.1% during the 4th quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock worth $1,111,854,000 after acquiring an additional 988,856 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is owned by corporate insiders.

Amgen Trading Up 4.5%

Shares of Amgen stock opened at $393.10 on Wednesday. The firm has a market capitalization of $212.16 billion, a PE ratio of 27.36, a P/E/G ratio of 3.81 and a beta of 0.41. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $398.00. The firm’s 50-day moving average price is $353.56 and its 200 day moving average price is $352.71. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period in the previous year, the business earned $4.90 EPS. Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts predict that Amgen Inc. will post 22.31 EPS for the current fiscal year.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Investor attention around AMGN has increased, potentially supporting trading interest as the company approaches its second-quarter results. Amgen investor attention article
• Neutral Sentiment: Amgen will release its second-quarter 2026 financial results after the U.S. market closes on August 4 and host an investor conference call at 4:30 p.m. ET. The announcement gives investors a near-term catalyst, with management expected to discuss results and outlook. Amgen second-quarter webcast announcement
• Negative Sentiment: An earnings preview projects that Amgen’s second-quarter earnings may decline and suggests the company lacks the factors typically associated with a likely earnings beat. That could weigh on expectations ahead of the August 4 report. Amgen Q2 earnings preview
• Negative Sentiment: Amgen halted a late-stage Phase 3 study of rocatinlimab in prurigo nodularis, resetting expectations for the drug in dermatology. The development removes or delays a potential source of future growth and adds uncertainty to the company’s pipeline. Rocatinlimab Phase 3 study article

Analyst Ratings Changes

A number of equities analysts recently weighed in on AMGN shares. Royal Bank Of Canada reaffirmed a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. The Goldman Sachs Group set a $389.00 price objective on Amgen in a research report on Friday, June 5th. BMO Capital Markets reaffirmed an “outperform” rating and set a $400.00 target price on shares of Amgen in a research note on Wednesday, July 1st. Finally, Truist Financial increased their target price on Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $356.62.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.